

Marie-Louise FrÃ©mond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735663/publications.pdf>

Version: 2024-02-01

54
papers

2,716
citations

279798

23
h-index

243625

44
g-index

58
all docs

58
docs citations

58
times ranked

4097
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI). <i>Cells</i> , 2022, 11, 318.	4.1	28
2	Systemic inflammatory syndrome in children with <i>FARSA</i> deficiency. <i>Clinical Genetics</i> , 2022, 101, 552-558.	2.0	7
3	Complex Allele with Additive Gain-of-Function STING1 Variants in a Patient with Cavitating Lung Lesions and Aspergillosis. <i>Journal of Clinical Immunology</i> , 2022, 42, 1156-1159.	3.8	4
4	COPA syndrome, 5 years after: Where are we?. <i>Joint Bone Spine</i> , 2021, 88, 105070.	1.6	21
5	Rheumatoid factor positive polyarticular juvenile idiopathic arthritis associated with a novel <i>COPA</i> mutation. <i>Rheumatology</i> , 2021, 60, e171-e173.	1.9	6
6	Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 803-818.e11.	3.8	98
7	Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. <i>Journal of Clinical Immunology</i> , 2021, 41, 603-609.	3.8	16
8	Life-Saving, Dose-Adjusted, Targeted Therapy in a Patient with a STAT3 Gain-of-Function Mutation. <i>Journal of Clinical Immunology</i> , 2021, 41, 807-810.	3.8	10
9	JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. <i>Rheumatology</i> , 2021, 60, 5801-5808.	1.9	52
10	STING-Mediated Lung Inflammation and Beyond. <i>Journal of Clinical Immunology</i> , 2021, 41, 501-514.	3.8	48
11	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	185
12	Syndrome COPA, quoi de neuf cinq ans aprÃ©s? <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 183-189.	0.0	0
13	JAK inhibition in the type I interferonopathies. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 991-993.	2.9	19
14	Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	43
15	Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 717388.	4.8	23
16	Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage. <i>Thorax</i> , 2020, 75, 92-95.	5.6	36
17	Bone Marrow Transplantation in Congenital Erythropoietic Porphyria: Sustained Efficacy but Unexpected Liver Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 704-711.	2.0	10
18	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-Î± signalling. <i>Rheumatology</i> , 2020, 59, 1927-1937.	1.9	26

#	ARTICLE	IF	CITATIONS
19	cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. <i>Nature Genetics</i> , 2020, 52, 1364-1372.	21.4	105
20	JAK Inhibition in the Aicardi-Goutières Syndrome. <i>New England Journal of Medicine</i> , 2020, 383, 2190-2193.	27.0	24
21	Mutations in <i>COPA</i> lead to abnormal trafficking of STING to the Golgi and interferon signaling. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	130
22	Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics. <i>Current Rheumatology Reports</i> , 2020, 22, 32.	4.7	30
23	Mendelian disorders of immunity related to an upregulation of type I interferon. , 2020, , 751-772.		2
24	Comment on: "Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors" by Giannelou et al: mutations in TRNT1 result in a constitutive activation of type I interferon signalling. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e86-e86.	0.9	12
25	COPA Syndrome as a Cause of Lupus Nephritis. <i>Kidney International Reports</i> , 2019, 4, 1187-1189.	0.8	19
26	Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1363-1373.	2.0	78
27	OP0107...HETEROZYGOUS MUTATIONS IN COPA ARE ASSOCIATED WITH ENHANCED TYPE I INTERFERON SIGNALLING. , 2019, , .		0
28	Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 431-433.	0.9	53
29	Inherited Immunodeficiency: A New Association With Early-Onset Childhood Panniculitis. <i>Pediatrics</i> , 2018, 141, S496-S500.	2.1	24
30	Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency. <i>Thorax</i> , 2018, 73, 590-592.	5.6	24
31	Reverse-Transcriptase Inhibitors in the Aicardi-Goutières Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2275-2277.	27.0	106
32	A child with severe juvenile dermatomyositis treated with ruxolitinib. <i>Brain</i> , 2018, 141, e80-e80.	7.6	58
33	COPA syndrome restricted to life-threatening alveolar hemorrhages: clinical, pathological, molecular and biological characterization. , 2018, , .		1
34	Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 543-552.e5.	2.9	159
35	Brief Report: Blockade of TANK-Binding Kinase 1/IKKε Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells. <i>Arthritis and Rheumatology</i> , 2017, 69, 1495-1501.	5.6	22
36	Detection of interferon alpha protein reveals differential levels and cellular sources in disease. <i>Journal of Experimental Medicine</i> , 2017, 214, 1547-1555.	8.5	288

#	ARTICLE	IF	CITATIONS
37	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. <i>Journal of Clinical Immunology</i> , 2017, 37, 123-132.	3.8	163
38	Type I interferon-mediated autoinflammation due to DNase II deficiency. <i>Nature Communications</i> , 2017, 8, 2176.	12.8	164
39	JAK inhibition in STING-associated interferonopathy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e75-e75.	0.9	22
40	O11 Monogenic type I interferonopathies: from diagnosis to treatment. <i>Journal of Investigative Dermatology</i> , 2016, 136, S162.	0.7	0
41	Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1752-1755.	2.9	192
42	SAT0514...Mosaic Tetrasomy 9P: A Mendelian Condition Associated with Pediatric-Onset Overlap Myositis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 846.2-846.	0.9	0
43	Mosaic tetrasomy 9p: a mendelian interferonopathy associated with pediatric-onset overlap myositis. <i>Pediatric Rheumatology</i> , 2015, 13, P140.	2.1	0
44	Next-Generation Sequencing for Diagnosis and Tailored Therapy: A Case Report of Astrovirus-Associated Progressive Encephalitis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e53-e57.	1.3	116
45	Mosaic Tetrasomy 9p: A Mendelian Condition Associated With Pediatric-Onset Overlap Myositis. <i>Pediatrics</i> , 2015, 136, e544-e547.	2.1	10
46	Inherited CARD9 Deficiency in 2 Unrelated Patients With Invasive <i>Exophiala</i> Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 1241-1250.	4.0	141
47	Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT). <i>Blood</i> , 2015, 126, 4326-4326.	1.4	0
48	Digestive perianastomotic ulcerations and Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1624-1631.	1.3	17
49	Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 183.	2.7	48
50	Circulating endothelial cells as markers of endothelial dysfunction during hematopoietic stem cell transplantation for pediatric primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1203-1206.	2.9	12
51	Anti-TNF- α Therapy May Cause Neonatal Neutropenia. <i>Pediatrics</i> , 2014, 134, e1189-e1193.	2.1	54
52	Cellular and humoral immunity elicited by influenza vaccines in pediatric hematopoietic-stem cell transplantation. <i>Human Immunology</i> , 2012, 73, 884-890.	2.4	10
53	CD4 T-Cell Response to Pandemic H1N1 Specific Vaccine After HSCT In Pediatric Recipients. <i>Blood</i> , 2010, 116, 2338-2338.	1.4	0
54	A child with severe juvenile dermatomyositis treated with ruxolitinib. <i>Journal of Financial Econometrics</i> , 0, , .	1.5	0